Axsome Therapeutics (AXSM) Debt to Equity (2016 - 2026)

Axsome Therapeutics has disclosed Debt to Equity across 11 years of filings, most recently posting $2.36 for Q1 2026.

• Debt to Equity for Q1 2026 came in at $2.36, down 33.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.36 (down 33.82% YoY), and the FY2025 annual result was $1.45, down 54.35% from the prior year.
• Debt to Equity came in at $2.36 for Q1 2026 at Axsome Therapeutics, up from $1.45 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $6.54 in Q2 2022 to a low of $0.64 in Q3 2022.
• The 5-year median for Debt to Equity is $1.73 (2025), against an average of $2.06.
• Across the five-year window, Debt to Equity surged 855.82% in 2022 and sank 89.96% in 2023, its largest moves.
• Axsome Therapeutics' Debt to Equity stood at $0.91 in 2022, then advanced by 5.66% to $0.97 in 2023, then soared by 228.12% to $3.17 in 2024, then slumped by 54.35% to $1.45 in 2025, then jumped by 63.32% to $2.36 in 2026.
• The last three Debt to Equity figures came in at $2.36 (Q1 2026), $1.45 (Q4 2025), and $1.73 (Q3 2025), per Business Quant data.